Osteoporosis following heart transplantation and immunosuppressive therapy

Research output: Contribution to journalArticlepeer-review

4 Citations (SciVal)


Heart transplantation (HT) remains the ultimate final therapy for patients with end-stage heart failure, who despite optimal medical and surgical treatments exhibit severe symptoms. To prevent rejection of the transplanted organ, HT patients require life-long immunosuppressive therapy. The goal of the immunosuppression is to minimise the risk of immune-mediated graft rejection, while avoiding clinical side-effects. Current immunosuppressive agents have yielded good survival outcome, however, complications of the immunosuppressive therapy, such as impaired bone strength and increased fracture risk, are common among HT patients rendering increased morbidity and mortality rates. The main aim of the present review was to summarise current knowledge on bone strength impairment after HT and concomitant immunosuppressive therapy.

Original languageEnglish
Pages (from-to)232-239
JournalTransplantation Reviews
Issue number4
Early online date2017 Aug 12
Publication statusPublished - 2017

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems


Dive into the research topics of 'Osteoporosis following heart transplantation and immunosuppressive therapy'. Together they form a unique fingerprint.

Cite this